Image not available

Figure 1. Flow diagram showing selection of the studies for the meta-analysis.

Image not available

Figure 2. Bar graph demonstrating the proportion of time spent in therapeutic anticoagulation across the included studies. INR indicates international normalized ratio. See the “Results” section for expansions of the study names.

Image not available

Figure 3. Forest plots demonstrating pooled estimates of safety outcomes. All the estimates were derived from random-effects modeling. A, Stroke or non–central nervous system embolism. B, Myocardial infarction. C, All-cause mortality. D, Composite outcome. See the “Results” section for expansions of the study names. Diamonds indicate the overall summary estimate for the analysis (width of the diamond represents the 95% CI).

Table 1. Characteristics of the 8 Included Trialsa
Image not available
Table 2. Baseline Characteristics of Included Patients Across Clinical Trials in the Warfarin Arma
Image not available
Table 3. Summary of Efficacy and Safety Outcomes Derived From the Warfarin Arm of Included Trialsa
Image not available
Table 4. Event Rates (95% CIs) of Stroke and Non-CNS Embolism in the Warfarin Arm Across Trials Stratified by Prespecified Subgroupsa
Image not available
Table 5. Summary Statistics Obtained From the Studies Included in the Previous Meta-analysis2a
Image not available
Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study.  Stroke. 1991;22(8):983-988PubMedArticle
Hart RG, Benavente O, McBride R, Pearce LA. Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis.  Ann Intern Med. 1999;131(7):492-501PubMed
Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation.  Ann Intern Med. 2007;146(12):857-867PubMed
Albers GW, Diener HC, Frison L,  et al; SPORTIF Executive Steering Committee for the SPORTIF V Investigators.  Ximelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: a randomized trial.  JAMA. 2005;293(6):690-698PubMedArticle
Olsson SB.Executive Steering Committee of the SPORTIF III Investigators.  Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised controlled trial.  Lancet. 2003;362(9397):1691-1698PubMedArticle
Connolly SJ, Ezekowitz MD, Yusuf S,  et al;  RE-LY Steering Committee and Investigators.  Dabigatran versus warfarin in patients with atrial fibrillation.  N Engl J Med. 2009;361(12):1139-1151PubMedArticle
Bousser MG, Bouthier J, Büller HR,  et al; Amadeus Investigators.  Comparison of idraparinux with vitamin K antagonists for prevention of thromboembolism in patients with atrial fibrillation: a randomised, open-label, non-inferiority trial.  Lancet. 2008;371(9609):315-321PubMedArticle
Patel MR, Mahaffey KW, Garg J,  et al; ROCKET AF Investigators.  Rivaroxaban versus warfarin in nonvalvular atrial fibrillation.  N Engl J Med. 2011;365(10):883-891PubMedArticle
Granger CB, Alexander JH, McMurray JJ,  et al;  ARISTOTLE Committees and Investigators.  Apixaban versus warfarin in patients with atrial fibrillation.  N Engl J Med. 2011;365(11):981-992PubMedArticle
Stewart RA. Clinical trials of direct thrombin and factor Xa inhibitors in atrial fibrillation.  Curr Opin Cardiol. 2011;26(4):294-299PubMedArticle
De Caterina R, Hylek EM. Stroke prevention in atrial fibrillation: current status and near-future directions.  Am J Med. 2011;124(9):793-799PubMedArticle
Jadad AR, Moore RA, Carroll D,  et al.  Assessing the quality of reports of randomized clinical trials: is blinding necessary?  Control Clin Trials. 1996;17(1):1-12PubMedArticle
Mant J, Hobbs FD, Fletcher K,  et al; BAFTA Investigators; Midland Research Practices Network (MidReC).  Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial.  Lancet. 2007;370(9586):493-503PubMedArticle
Connolly S, Pogue J, Hart R,  et al; ACTIVE Writing Group of the ACTIVE Investigators.  Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial.  Lancet. 2006;367(9526):1903-1912PubMedArticle
Moher D, Liberati A, Tetzlaff J, Altman DG. PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement.  PLoS Med. 2009;6(7):e1000097 Accessed October 2, 2011Article
Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias.  Biometrics. 1994;50(4):1088-1101PubMedArticle
Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators.  The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation.  N Engl J Med. 1990;323(22):1505-1511PubMedArticle
Ezekowitz MD, Bridgers SL, James KE,  et al; Veterans Affairs Stroke Prevention in Nonrheumatic Atrial Fibrillation Investigators.  Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation.  N Engl J Med. 1992;327(20):1406-1412PubMedArticle
 Stroke Prevention in Atrial Fibrillation Study: final results.  Circulation. 1991;84(2):527-539PubMed
Petersen P, Boysen G, Godtfredsen J, Andersen ED, Andersen B. Placebo-controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation: the Copenhagen AFASAK study.  Lancet. 1989;1(8631):175-179PubMedArticle
Connolly SJ, Laupacis A, Gent M, Roberts RS, Cairns JA, Joyner C. Canadian Atrial Fibrillation Anticoagulation (CAFA) Study.  J Am Coll Cardiol. 1991;18(2):349-355PubMedArticle
EAFT (European Atrial Fibrillation Trial) Study Group.  Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke.  Lancet. 1993;342(8882):1255-1262PubMed
Gage BF, Cardinalli AB, Albers GW, Owens DK. Cost-effectiveness of warfarin and aspirin for prophylaxis of stroke in patients with nonvalvular atrial fibrillation.  JAMA. 1995;274(23):1839-1845PubMedArticle
Thomson R, Parkin D, Eccles M, Sudlow M, Robinson A. Decision analysis and guidelines for anticoagulant therapy to prevent stroke in patients with atrial fibrillation.  Lancet. 2000;355(9208):956-962PubMedArticle
O’Brien CL, Gage BF. Costs and effectiveness of ximelagatran for stroke prophylaxis in chronic atrial fibrillation.  JAMA. 2005;293(6):699-706PubMedArticle
Jowett S, Bryan S, Mant J,  et al.  Cost effectiveness of warfarin versus aspirin in patients older than 75 years with atrial fibrillation.  Stroke. 2011;42(6):1717-1721PubMedArticle
Sorensen SV, Dewilde S, Singer DE, Goldhaber SZ, Monz BU, Plumb JM. Cost-effectiveness of warfarin: trial versus “real-world” stroke prevention in atrial fibrillation.  Am Heart J. 2009;157(6):1064-1073PubMedArticle
Amarenco P, Goldstein LB, Messig M,  et al; SPARCL Investigators.  Relative and cumulative effects of lipid and blood pressure control in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels trial.  Stroke. 2009;40(7):2486-2492PubMedArticle
Ovbiagele B, Schwamm LH, Smith EE,  et al.  Recent nationwide trends in discharge statin treatment of hospitalized patients with stroke.  Stroke. 2010;41(7):1508-1513PubMedArticle
Review Article
Apr 23, 2012

Current Trial-Associated Outcomes With Warfarin in Prevention of Stroke in Patients With Nonvalvular Atrial FibrillationA Meta-analysis

Author Affiliations

Author Affiliations: Department of Cardiovascular Medicine, Heart and Vascular Institute, Cleveland Clinic, Cleveland, Ohio.

Arch Intern Med. 2012;172(8):623-631. doi:10.1001/archinternmed.2012.121